WEKO3
アイテム
Carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix
https://repo.qst.go.jp/records/68717
https://repo.qst.go.jp/records/68717911b000a-d96b-4c28-becb-90e0513360eb
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2006-10-16 | |||||
| タイトル | ||||||
| タイトル | Carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kato, Shingo
× Kato, Shingo× 加藤 眞吾 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: To evaluate the toxicity and efficacy of carbon ion radiotherapy (CIRT) for locally advanced adenocarcinoma of the uterine cervix by a phase I/II dose-escalation study. Methods and Materials: Between April 1998 and August 2005, 26 patients with adenocarcinoma of the uterine cervix were treated with CIRT. The mean age of the patients was 60 years. Histologically, 19 patients had adenocarcinomas and 7 had adenosquamous cell carcinomas. Seven patients had stage IIB, 17 had stage IIIB, and 2 had stage IVA disease. The median tumor size was 6.0 cm. The treatment consisted of whole pelvic irradiation and local boost. The clinical target volume (CTV) of whole pelvic irradiation included the cervical tumor, uterus, parametrium, at least the upper half of the vagina, and pelvic lymph nodes. The dose of the whole pelvic irradiation was fixed at 36.0 gray equivalent (GyE) in 12 fractions. In local boost irradiation, the CTV was shrunk to the cervical tumor and surrounding tissues. A dose escalation study was performed with an initial dose of 26.4 GyE/8 fractions, and the dose was gradually increased up to 35.2 GyE/8 fractions (total dose: 62.4-71.2 GyE). The dose to the GI tracts was limited to less than 60 GyE. The median follow-up duration for the surviving patients was 34 months (range, 8-74 months). Results: No patient developed severe acute toxicity. Three patients developed grade 1 late rectal complications and 2 developed grade 1 late bladder complications. One patient who received 68.0 GyE developed rectovaginal fistula 14 months after CIRT. Local tumor control was obtained in 4 of the 7 patients (57%) who received a total of 62.4-64.8 GyE, in 7 of the 9 patients (78%)who received 68.0 GyE, and 9 of the 9 patients (100%) who received 71.2GyE. The 3-year local control rate for all patients was 71%. Three patients who had developed local recurrence were surgically salvaged. The 3-year overall survival rates for all patients and the 17 patients with stage IIIB or IVA disease were 65% and 58%, respectively. Conclusions: Although the number of patients was small, the results suggested that CIRT provided favorable local tumor control and overall survival with acceptable rates of late complications in the treatment of locally advanced adenocarcinoma of the uterine cervix. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | ESTRO25 | |||||
| 発表年月日 | ||||||
| 日付 | 2006-10-12 | |||||
| 日付タイプ | Issued | |||||
